<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228189</url>
  </required_header>
  <id_info>
    <org_study_id>920-03-250</org_study_id>
    <secondary_id>NWO920-03-250</secondary_id>
    <nct_id>NCT00228189</nct_id>
  </id_info>
  <brief_title>Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients</brief_title>
  <official_title>Induction of Specific T Cell Responses in Colorectal Cancer Patients With Liver Metastases Upon Vaccination With Autologous Dendritic Cells Pulsed With CEA-peptide or Electroporated With CEA-RNA: Evaluation of in Vivo Immune Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As
      such they are currently used in clinical vaccination protocols in cancer patients. We
      evaluate the ability of mature DCs pulsed with carcinoembryonic antigen (CEA)-peptide (arm A)
      or electroporated with CEA-mRNA (arm B) to induce CEA-specific T cell responses in patients
      with resectable liver metastases from colorectal cancer. To evaluate immune responses,
      CEA-specific T cell reactivity is monitored in peripheral blood, resected abdominal lymph
      nodes, tumor tissue and biopsies of vaccination sites and post-treatment DTH skin tests.
      Patients are vaccinated intradermally and intravenously with CEA-peptide pulsed mature DCs
      three times prior to resection of liver metastases. In 2007 a side-study has been added (arm
      C), in which patients with stage III or high-risk stage II colorectal cancer that are
      amenable for standard adjuvant oxaliplatin/capecitabine therapy are vaccinated with
      CEApeptide-pulsed DCs. Also in this group, safety and immune responses in peripheral blood
      and the DTH-skin test are the primary endpoints. Results are compared with the results
      obtained in arm A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunological response against carcinoembryonic antigen and the control protein KLH</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>During the study</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dendritic cells pulsed with CEA-peptide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells electroporated with CEA-mRNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CEA-loaded dendritic cell vaccine</intervention_name>
    <description>Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For arm A and B

        Inclusion Criteria:

          1. Histological documented evidence of colorectal cancer.

          2. Primary tumor surgically removed, recurrence(s) in the liver.

          3. Planned surgical excision of liver metastases.

          4. HLA-A2.1 phenotype according to lymphocyte HLA typing.

          5. Expression of CEA on primary tumor.

          6. ECOG performance status 0-1, life expectancy &gt; 3 months.

          7. Age 18-75 years.

          8. WBC &gt; 3.0 x 109/l, lymphocytes &gt; 0.8 x 109/l, platelets &gt; 100 x 109/l, serum
             creatinine &lt; 150 μmol/l, serum bilirubin &lt; 25 μmol/l.

          9. Expected adequacy of follow-up.

         10. Written informed consent.

        Exclusion Criteria:

          1. Clinical signs of extra hepatic metastases, in patients with a clinical suspicion of
             other metastases diagnostic tests should be performed to exclude this.

          2. Prior chemotherapy, immunotherapy, or radiotherapy within three months before planned
             surgical excision is allowed.

          3. A history of myocardial infarction, angina pectoris, cardiac arrhythmias,
             cerebrovascular accidents, transient ischemic attacks or severe hypertension
             (exclusion criteria for autologous blood donation)

          4. Concomitant use of corticosteroids or other immunosuppressive agents.

          5. A history of any second malignancy in the past five years excluding adequately treated
             basal carcinoma of skin or carcinoma in situ of cervix.

          6. Serious concomitant disease, active infections. Specifically, patients with autoimmune
             disease or organ allografts and patients with a history of HBsAg or HIV are excluded.

          7. A known allergy to shell fish.

          8. Pregnant or lactating women.

        For arm C (side-study)

        inclusion criteria:

          1. histological proof of colorectal cancer

          2. HLA-A0201 positive

          3. stage III (T1-4N1-2M0) cancer or high risk stage II (T4 and/or poor differentiation in
             histology and/or perforation and/or obstruction and/or venous invasion and/or
             histological analysis of ≤10 lymph nodes)

          4. ≤ 8 weeks since surgical resection of primary colorectal tumor

          5. Age 18-75 years

          6. WHO performance 0-1 (Karnofsky 100-70%)

          7. WBC ≥ 3.0x109/l

          8. Platelets ≥ 100x109/l

          9. Hb ≥ 6 mmol/l

         10. Total bilirubin ≤ 2x UNL

         11. ASAT and ALAT ≤ 3x UNL

         12. Serum creatinine ≤ 1.5 x UNL

         13. Expected adequacy of follow-up

         14. Signed written informed consent

        exclusion criteria

          1. A history of second malignancy within the last 5 years. Adequately treated basal
             carcino¬ma of skin or carcinoma in situ of cervix is acceptable within this period

          2. Serious concomitant disease. Autoimmune disease or organ grafts.

          3. Other serious concomitant diseases preventing the safe administration of study drugs
             or likely to interfere with the study assessments.

          4. A known allergy to shell fish (contains KLH)

          5. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. dr. C.J.A. Punt, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center, dept. of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center, dept. of Medical Oncology</name>
      <address>
        <city>Nijmegen</city>
        <zip>P.O. box 9101 6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcn.nl</url>
    <description>Home page of the Radboud University Nijmegen Medical Center</description>
  </link>
  <link>
    <url>http://www.ncmls.nl/til/Tumorimmunology.asp</url>
    <description>Website of the tumor immunology department of the Nijmegen Center for Molecular Life Sciences of the Radboud University Nijmegen Medical Center</description>
  </link>
  <reference>
    <citation>Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004 May;10(5):475-80. Review.</citation>
    <PMID>15122249</PMID>
  </reference>
  <reference>
    <citation>Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol. 2008 May;66(2):118-34. doi: 10.1016/j.critrevonc.2007.12.007. Epub 2008 Feb 8. Review.</citation>
    <PMID>18262431</PMID>
  </reference>
  <reference>
    <citation>de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005 Aug 20;23(24):5779-87.</citation>
    <PMID>16110035</PMID>
  </reference>
  <results_reference>
    <citation>Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol. 2006 Jun;17(6):974-80. Epub 2006 Apr 6.</citation>
    <PMID>16600979</PMID>
  </results_reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>November 26, 2010</last_update_submitted>
  <last_update_submitted_qc>November 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>C.J.A. Punt, MD, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>Dendritic cells</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Carcinoembryonic antigen</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

